CD8A and neoplasm: In addition, FA-CS-R848/DOX@Lip increased the MHC II/CD206 ratio of tumor-associated macrophages (TAMs), elevated the proportions of CD8<sup>+</sup> and CD4<sup>+</sup> T cells, reduced the proportion of myeloid-derived suppressor cells (MDSCs), and enhanced the percentages of IFNγ<sup>+</sup> and Ki67<sup>+</sup> CD8<sup>+</sup> T cells <i>in vivo</i>.